☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
SetPoint Medical
SetPoint Medical Reports the US FDA’s IDE Approval to Initiate Neuroimmune Modulation Platform’s Evaluation for Relapsing-Remittin...
October 3, 2024
SetPoint Medical’s Neuroimmune Modulation Platform Obtains the US FDA’s Breakthrough Device Designation to Treat Multiple Sclerosi...
March 14, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.